Saturday 17 October 2026 Export PDEX’s income statement to Excel — free account

Pro-Dex, Inc.

PDEX Healthcare Medical Instruments & Supplies

Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025. In the quarter to June 2026, revenue grew 16.7%, EPS grew 143.2%, free cash flow fell 79.0% and total debt rose 43.5%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

58.26 1.76 −2.93%

Follow PDEX

Alert me

Market cap: $194.1M
P/E: 13.8×
Fwd P/E: 23.5×
Dividend yield: —
F-score: 6/9
Altman Z: 7.38
Beneish M: −1.11
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	1	—	—	—	3	—

Insider Ownership 36.45%

Capital & Financial Ratios $m

Market Cap 194.06

Revenue 77.55

Net Income 13.66

Free Cash Flow 6.76

Net Debt 3.92

Current Ratio 4.10

Debt/Equity 0.28

P/E ratio 13.77

Fwd P/E 23.50

P/S ratio 2.42

P/B ratio 3.95

Past 5Y EPS Growth 21.32%

This Y EPS Growth (25.00%)

Next Y EPS Growth 8.74%

Next Y revenue growth 6.64%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 35.53%

10-year low 10-year high

P/S against its own 10 years 79.43%

10-year low 10-year high

P/B against its own 10 years 74.16%

10-year low 10-year high

EV/Sales against its own 10 years 82.90%

10-year low 10-year high

EV/FCF against its own 10 years 75.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	4	7	7	9
Receivables	10	14	17	22
Inventory	16	15	22	21
Other	—	—	—	—
	31	37	47	53

	2023	2024	2025	2026
Payables	2	5	5	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	10	13	15	13

Compound Annual Growth %

	10y	5y	3y
Sales	14.99%	15.32%	18.94%
Cash Flow	31.57%	0.00%	9.86%
Earnings	32.45%	17.23%	24.53%
Book Value	18.29%	18.85%	14.67%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	19	19	20	20	78
’25	15	17	17	17	67
’24	12	13	14	15	54
’23	11	11	13	11	46
’22	10	10	9	13	42
’21	9	8	12	9	38

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	2	4	2	0	7
’25	2	(4)	1	0	(2)
’24	0	1	4	1	6
’23	3	0	2	1	5
’22	3	2	0	(5)	(1)
’21	(1)	2	(4)	1	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	2	4	2	0	7
’25	1	(5)	1	0	(3)
’24	0	0	4	1	5
’23	3	(1)	2	0	4
’22	2	1	0	(6)	(3)
’21	(1)	(5)	(4)	0	(10)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	1.40	0.66	1.20	0.87	4.12
’25	0.75	0.61	0.98	0.36	2.67
’24	(0.17)	0.14	0.19	0.46	0.60
’23	0.29	0.75	0.36	0.42	1.95
’22	0.28	0.25	0.12	0.56	1.02
’21	0.32	0.44	0.50	0.22	1.57

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	4.30	6.05	10.37	12.83	20.06	12.40	14.51	16.18	23.47	36.57	Analyst estimates 2027–2029 Powerpack
	High	8.00	16.00	17.95	42.60	38.45	26.51	19.68	54.84	70.26	77.00
People
People	Employees	76	80	97	117	118	135	146	148	181	206
	Revenue/emp, $m	0.29	0.28	0.28	0.30	0.32	0.31	0.32	0.36	0.37	0.38
Income, $m
Income, $m	Revenue	22	22	27	35	38	42	46	54	67	78
	Gross margin, %	32.75	35.36	35.99	37.73	35.70	31.24	27.66	27.02	29.30	31.38
	EBT	3	3	5	8	8	6	9	3	12	18
	EBT margin, %	12.54	11.62	20.05	22.68	20.03	13.54	20.46	4.89	18.11	23.23
	Net income	5	2	4	6	6	5	7	2	9	14
	Depreciation	1	2	0	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	5.43	5.22	6.48	8.91	10.02	11.56	12.91	15.39	20.25	24.04
	Earnings	1.26	0.38	0.99	1.56	1.63	1.06	1.98	0.61	2.73	4.24
	Cash flow	0.80	0.72	0.79	1.26	(0.55)	(0.23)	1.53	1.78	(0.51)	2.24
	Capex	(0.16)	(0.21)	(0.33)	(0.14)	(2.19)	(0.46)	(0.27)	(0.28)	(0.38)	(0.15)
	Free cash flow	0.64	0.51	0.46	1.12	(2.73)	(0.69)	1.26	1.50	(0.89)	2.10
	Book value	3.39	4.01	4.06	4.87	5.29	6.99	8.85	8.82	11.14	14.77
	Shares, m	4	4	4	4	4	4	4	3	3	3
Valuation, ×
Valuation, ×	P/E	4.88	17.37	13.42	11.37	19.93	12.70	10.27	29.13	15.81	13.84
	P/S	1.13	1.26	2.05	2.00	3.05	1.38	1.48	1.19	2.15	2.44
	P/B	1.81	1.64	3.28	3.66	5.78	2.28	2.16	2.08	3.92	3.97
	EV/Sales	0.91	0.94	1.85	1.84	3.22	1.59	1.59	1.21	2.19	2.49
	EV/FCF	7.69	9.59	25.94	14.59	(11.80)	(26.47)	16.40	12.46	(49.16)	28.67
Cash, $m
Cash, $m	Operating cash flow	3	3	3	5	(2)	(1)	5	6	(2)	7
	Capex	(1)	(1)	(1)	(1)	(8)	(2)	(1)	(1)	(1)	0
	Free cash flow	3	2	2	4	(10)	(3)	4	5	(3)	7
Balance, $m
Balance, $m	Working capital	10	14	17	17	19	20	21	24	33	40
	Total debt	0	0	4	3	12	10	9	8	9	13
	Net debt	(5)	(7)	(6)	(6)	7	9	5	1	2	4
	Shareholders’ equity	14	17	17	19	20	25	32	31	37	48
Returns, %
Returns, %	ROA	36.98	8.94	18.26	21.58	17.27	10.23	14.02	4.08	15.80	20.14
	ROIC	19.33	15.14	27.19	33.05	10.63	9.40	9.89	14.21	17.25	15.75
	ROE	45.02	10.46	24.20	33.89	31.52	20.09	24.81	6.81	26.60	32.43

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EMBC Embecta Corp.	$365.5M	4.2×	3.8×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
ZJYL Jin Medical International Ltd.	$340.9M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%	Compare
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%
KRMD KORU Medical Systems, Inc.	$139.9M	— (loss-making)	— (loss-making)	+18.15% (above 0%: growing)	n/m	+26.17% (above 0%: growing)	65.14%	5.21%	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)	Compare
Median of peers	$250.3M	—	28.7×	−1.93%	—	−0.48%	57.46%	5.77%

All 55 Medical Instruments & Supplies stocks →

Pro-Dex, Inc. (PDEX) key facts

Strength: Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025.
Pro-Dex, Inc. (PDEX) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PDEX traded at $58.26, a market capitalization of $194.1 million.
Return on equity was 32.4% and debt-to-equity 0.28.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.38 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.